[
  {
    "ts": null,
    "headline": "Gilead's twice-yearly HIV prevention injection gets FDA approval",
    "summary": "The US Food and Drug Administration has approved Gilead's (GILD) new HIV prevention drug. The drug, lenacapavir, only requires an injection every 6 months. Yahoo Finance Healthcare Reporter Anjalee Khemlani reports the details. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
    "url": "https://finnhub.io/api/news?id=9b8dbf4a8a788b285c5a0f10cdd7a8d194153d5fd81307a474bc35ec4e4de9e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750281132,
      "headline": "Gilead's twice-yearly HIV prevention injection gets FDA approval",
      "id": 135376377,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The US Food and Drug Administration has approved Gilead's (GILD) new HIV prevention drug. The drug, lenacapavir, only requires an injection every 6 months. Yahoo Finance Healthcare Reporter Anjalee Khemlani reports the details. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.",
      "url": "https://finnhub.io/api/news?id=9b8dbf4a8a788b285c5a0f10cdd7a8d194153d5fd81307a474bc35ec4e4de9e2"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
    "summary": "Health care stocks were decreasing late Wednesday afternoon, with the NYSE Health Care Index down 0.",
    "url": "https://finnhub.io/api/news?id=1fb2a5d16ceb2e78dac5a33b9c6272b2ca9572725430a156a3e385873c5c41c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750276154,
      "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
      "id": 135374965,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Health care stocks were decreasing late Wednesday afternoon, with the NYSE Health Care Index down 0.",
      "url": "https://finnhub.io/api/news?id=1fb2a5d16ceb2e78dac5a33b9c6272b2ca9572725430a156a3e385873c5c41c8"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Powerful Twice-Yearly Treatment to Prevent HIV",
    "summary": "Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections.",
    "url": "https://finnhub.io/api/news?id=1190edb1a9123239942bc934d32dcb0cd62039dfc4a35dbbc58aaac70f1104b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750275780,
      "headline": "FDA Approves Powerful Twice-Yearly Treatment to Prevent HIV",
      "id": 135376379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections.",
      "url": "https://finnhub.io/api/news?id=1190edb1a9123239942bc934d32dcb0cd62039dfc4a35dbbc58aaac70f1104b3"
    }
  },
  {
    "ts": null,
    "headline": "Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection",
    "summary": "FOSTER CITY, Calif., June 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the United States for people who need or want PrEP. Data show that ≥99.9% of participan",
    "url": "https://finnhub.io/api/news?id=ae0b50027902241c495205fb10e04c845d5e9d542388df95a729d49962637e95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750272540,
      "headline": "Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection",
      "id": 135376380,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., June 18, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the United States for people who need or want PrEP. Data show that ≥99.9% of participan",
      "url": "https://finnhub.io/api/news?id=ae0b50027902241c495205fb10e04c845d5e9d542388df95a729d49962637e95"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Flat as Traders Hedge on Rates -- Health Care Roundup",
    "summary": "Health-care companies were flat as traders hedged their bets on the outlook for interest rates. Gilead Sciences ticked down even after it won Food and Drug Administration approval for a highly...",
    "url": "https://finnhub.io/api/news?id=9f39bd6c58561f50ba6ebb59f19ea1d0781ad4144683584ab8bac12e4de46299",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750269008,
      "headline": "Health Care Flat as Traders Hedge on Rates -- Health Care Roundup",
      "id": 135374219,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Health-care companies were flat as traders hedged their bets on the outlook for interest rates. Gilead Sciences ticked down even after it won Food and Drug Administration approval for a highly...",
      "url": "https://finnhub.io/api/news?id=9f39bd6c58561f50ba6ebb59f19ea1d0781ad4144683584ab8bac12e4de46299"
    }
  },
  {
    "ts": null,
    "headline": "Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It?",
    "summary": "Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It?",
    "url": "https://finnhub.io/api/news?id=1a7c5eb6e5d6d28a29a284e8c88bbef5717b5fe2f679a0361421fce710b2eedb",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750264889,
      "headline": "Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It?",
      "id": 135391776,
      "image": "",
      "related": "GILD",
      "source": "DowJones",
      "summary": "Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It?",
      "url": "https://finnhub.io/api/news?id=1a7c5eb6e5d6d28a29a284e8c88bbef5717b5fe2f679a0361421fce710b2eedb"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.",
    "summary": "FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.",
    "url": "https://finnhub.io/api/news?id=e6bd456b06d179632756728828ec83ec6b06e6860e31ffaee0ce400ed930e198",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750262640,
      "headline": "FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.",
      "id": 135391798,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.",
      "url": "https://finnhub.io/api/news?id=e6bd456b06d179632756728828ec83ec6b06e6860e31ffaee0ce400ed930e198"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences' Twice-Yearly HIV-Prevention Drug Gets FDA Approval",
    "summary": "By Katherine Hamilton Gilead Sciences received approval from the Food and Drug Administration for its injectible pre-exposure prophylaxis designed to reduce the risk of sexually transmitted HIV....",
    "url": "https://finnhub.io/api/news?id=837620d6da1b379cf4768fc1aad2ed9c84e10d9507a29361b347722f1ffa37fe",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750261089,
      "headline": "Gilead Sciences' Twice-Yearly HIV-Prevention Drug Gets FDA Approval",
      "id": 135373565,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "By Katherine Hamilton Gilead Sciences received approval from the Food and Drug Administration for its injectible pre-exposure prophylaxis designed to reduce the risk of sexually transmitted HIV....",
      "url": "https://finnhub.io/api/news?id=837620d6da1b379cf4768fc1aad2ed9c84e10d9507a29361b347722f1ffa37fe"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves twice-yearly shot of Gilead drug for HIV prevention",
    "summary": "The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market dominated by oral medicines.",
    "url": "https://finnhub.io/api/news?id=a87439986c661a40d7bde7682454bc7b3eb6ff7cd20a832bf58a373fc0e48f26",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750258920,
      "headline": "FDA approves twice-yearly shot of Gilead drug for HIV prevention",
      "id": 135376381,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market dominated by oral medicines.",
      "url": "https://finnhub.io/api/news?id=a87439986c661a40d7bde7682454bc7b3eb6ff7cd20a832bf58a373fc0e48f26"
    }
  },
  {
    "ts": null,
    "headline": "US FDA approves Gilead's twice-yearly injection for HIV prevention",
    "summary": "The U.S. Food and DrugAdministration on Wednesday approved Gilead Scienceslenacapavir, a twice-yearly injection, for preventing HIVinfection in adults and adolescents. Gilead said the...",
    "url": "https://finnhub.io/api/news?id=86785c7fc28dfe09d0e35e903b463469b37b3ce9fa21062daeba1707e9988e64",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750257470,
      "headline": "US FDA approves Gilead's twice-yearly injection for HIV prevention",
      "id": 135372947,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "The U.S. Food and DrugAdministration on Wednesday approved Gilead Scienceslenacapavir, a twice-yearly injection, for preventing HIVinfection in adults and adolescents. Gilead said the...",
      "url": "https://finnhub.io/api/news?id=86785c7fc28dfe09d0e35e903b463469b37b3ce9fa21062daeba1707e9988e64"
    }
  },
  {
    "ts": null,
    "headline": "FDA Says Gilead's Yeztugo Receives FDA Approval For HIV Prevention",
    "summary": "FDA: * FDA: GILEAD'S YEZTUGO RECEIVES FDA APPROVAL FOR HIVPREVENTION ...",
    "url": "https://finnhub.io/api/news?id=66896992e1d8ee05a58779d6d2d01a739e9fe9f3673b0999b3d8d4376318d833",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750256648,
      "headline": "FDA Says Gilead's Yeztugo Receives FDA Approval For HIV Prevention",
      "id": 135372704,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "FDA: * FDA: GILEAD'S YEZTUGO RECEIVES FDA APPROVAL FOR HIVPREVENTION ...",
      "url": "https://finnhub.io/api/news?id=66896992e1d8ee05a58779d6d2d01a739e9fe9f3673b0999b3d8d4376318d833"
    }
  }
]